|Articles|February 19, 2003

VirtualScopics closes $3.8M financing

GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite

GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite of image analysis tools that detect and help characterize tiny changes in physical structures over time. The firm's image-based biomarker solutions are designed to accelerate the pharmaceutical R&D process by rapidly measuring the efficacy and safety of drug compounds. The technology might also be leveraged to improve treatment planning and diagnosis for patients. GE plans to collaborate with VirtualScopics to advance the application of its imaging technology in clinical trials. The firm's proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single 3D model.

Related to this article

Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Does kV Still Matter in Photon-Counting CT?
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
CT Radiation Dosing: Where Things Stand, Part 2
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).